These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9239804)

  • 21. Effect of ofloxacin and norfloxacin on rifampicin pharmacokinetics in man.
    Ezejiofor NA; Brown S; Barikpoar E; Orisakwe OE
    Am J Ther; 2015; 22(1):29-36. PubMed ID: 23817346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disposition of gamma-hydroxybutyric acid in conventional and nonconventional biologic fluids after single drug administration: issues in methodology and drug monitoring.
    Abanades S; Farré M; Segura M; Pichini S; Pastor A; Pacifici R; Pellegrini M; de la Torre R
    Ther Drug Monit; 2007 Feb; 29(1):64-70. PubMed ID: 17304152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose related pharmacokinetics of ofloxacin in healthy volunteers.
    Immanuel C; Hemanthkumar AK; Gurumurthy P; Venkatesan P
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):1017-22. PubMed ID: 12475149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma pooling to expedite bioequivalence estimation of rifampicin in fixed dose combinations.
    Panchagnula R; Parmar J; Kaur JK; Singh I; Bhade SR
    Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):161-7. PubMed ID: 16810342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
    Zwolska Z; Niemirowska-Mikulska H; Augustynowicz-Kopec E; Walkiewicz R; Stambrowska H; Safianowska A; Grubek-Jaworska H
    Int J Tuberc Lung Dis; 1998 Oct; 2(10):824-30. PubMed ID: 9783530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pharmacokinetic factors and bioavailability of rifampicin, isoniazid and pyrazinamid fixed in one dose capsule.
    Zwolska Z; Augustynowicz-Kopeć E; Niemirowska-Mikulska H
    Acta Pol Pharm; 2002; 59(6):448-52. PubMed ID: 12669769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis.
    Langdon G; Wilkins JJ; Smith PJ; McIlleron H
    Int J Tuberc Lung Dis; 2004 Jul; 8(7):862-7. PubMed ID: 15260278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron.
    Villikka K; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1999 Apr; 65(4):377-81. PubMed ID: 10223773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of bioavailability of two brands of rifampicin.
    Rewari S; Rath R; Gupta U
    J Assoc Physicians India; 1998 Aug; 46(8):751. PubMed ID: 11229300
    [No Abstract]   [Full Text] [Related]  

  • 30. [Lymphogenic introduction into lesser circulation of orally administered rifampicin in standard and liposomal forms].
    Petrenko TI; Ursov IG; Kurunov IuN; Borodin IuI; Sidorova LD
    Probl Tuberk; 1995; (3):53-4. PubMed ID: 7617640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Developement of serum and urine concentrations of rifampicin during treatment].
    Pechère JC; Tancrède C
    Pathol Biol (Paris); 1969 Feb; 17(3):155-8. PubMed ID: 4892933
    [No Abstract]   [Full Text] [Related]  

  • 32. The pharmacokinetics of oral rifampicin in AIDS patients.
    Jaruratanasirikul S
    J Med Assoc Thai; 1998 Jan; 81(1):25-8. PubMed ID: 9470318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of simulated weightlessness on the oral pharmacokinetics of acetaminophen as a gastric emptying probe in man: a plasma and a saliva study.
    Gandia P; Bareille MP; Saivin S; Le-Traon AP; Lavit M; Guell A; Houin G
    J Clin Pharmacol; 2003 Nov; 43(11):1235-43. PubMed ID: 14551178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microbiological assay versus spectrophotometry for determination of rifampicin in urine.
    George J; Bhatia VN; Balakrishnan S
    Indian J Lepr; 1988 Jan; 60(1):47-52. PubMed ID: 3060546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rifampicin serum levels in childhood tuberculosis.
    Thee S; Detjen A; Wahn U; Magdorf K
    Int J Tuberc Lung Dis; 2009 Sep; 13(9):1106-11. PubMed ID: 19723399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rifampicin markedly decreases plasma concentration and hypnotic effect of brotizolam.
    Ujiie Y; Fukasawa T; Yasui-Furukori N; Suzuki A; Tateishi T; Otani K
    Ther Drug Monit; 2006 Jun; 28(3):299-302. PubMed ID: 16778710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Saliva and plasma concentrations of isoniazid and acetylisoniazid in man.
    Hutchings AD; Monie RD; Spragg BP; Routledge PA
    Br J Clin Pharmacol; 1988 May; 25(5):585-9. PubMed ID: 3408638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prednisolone elimination in human saliva.
    Al-Habet SM; Rogers HJ
    Int J Clin Pharmacol Ther Toxicol; 1985 Sep; 23(9):485-7. PubMed ID: 4055160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative assay of rifampicin and three of its metabolites in human plasma, urine and saliva by high-performance liquid chromatography.
    Lecaillon JB; Febvre N; Metayer JP; Souppart C
    J Chromatogr; 1978 Mar; 145(2):319-24. PubMed ID: 649727
    [No Abstract]   [Full Text] [Related]  

  • 40. Local diffusibility of rifampicin in tuberculous lesions of bone and joint.
    Popescu E; Algeorge G; Paunescu E; Stoinescu M; Rudescu D
    Respiration; 1971; 28():Suppl:44-51. PubMed ID: 5150795
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.